Transenterix Company Profile (NYSE:TRXC)

About Transenterix (NYSE:TRXC)

Transenterix logoTransEnterix, Inc. is a medical device company. The Company is focused on the development and commercialization of ALF-X Surgical Robotic System (the ALF-X System), and SurgiBot System. The Company's ALF-X System is a multi-port robotic surgery system, which allows multiple robotic arms to control instruments and a camera. The system features advanced technology to enable surgeons with haptic feedback and the ability to move the camera through eye movement. The system replicates laparoscopic motion and integrates three-dimensional high definition (3DHD) vision technology. The ALF-X System also offers responsible economics to hospitals by offering robotic technology with reusable instruments. The SurgiBot System is designed as a single-incision, patient-side robotic-assisted surgery system. The Company also develops and manufactures laparoscopic surgical instruments that are used in abdominal surgery, such as scissors, graspers, clip appliers, and suction and irrigation instruments.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Medical Equipment, Supplies & Distribution
  • Sub-Industry: N/A
  • Symbol: NYSE:TRXC
  • CUSIP: N/A
  • Web:
  • Market Cap: $515.42 million
  • Outstanding Shares: 148,536,000
Average Prices:
  • 50 Day Moving Avg: $1.63
  • 200 Day Moving Avg: $0.95
  • 52 Week Range: $0.45 - $5.00
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -9.38
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $5.05 million
  • Price / Sales: 102.06
  • Book Value: $0.83 per share
  • Price / Book: 4.18
  • EBITDA: ($47,820,000.00)
  • Net Margins: -928.85%
  • Return on Equity: -49.16%
  • Return on Assets: -33.51%
  • Average Volume: 6.03 million shs.
  • Short Ratio: 5.58

Frequently Asked Questions for Transenterix (NYSE:TRXC)

What is Transenterix's stock symbol?

Transenterix trades on the New York Stock Exchange (NYSE) under the ticker symbol "TRXC."

How were Transenterix's earnings last quarter?

Transenterix Inc (NYSE:TRXC) posted its earnings results on Monday, March, 6th. The company reported ($0.12) EPS for the quarter, missing analysts' consensus estimates of ($0.11) by $0.01. Transenterix had a negative return on equity of 49.16% and a negative net margin of 928.85%. View Transenterix's Earnings History.

Where is Transenterix's stock going? Where will Transenterix's stock price be in 2017?

1 brokerages have issued 12-month price objectives for Transenterix's stock. Their forecasts range from $2.75 to $2.75. On average, they expect Transenterix's stock price to reach $2.75 in the next year. View Analyst Ratings for Transenterix.

Are investors shorting Transenterix?

Transenterix saw a drop in short interest during the month of September. As of September 29th, there was short interest totalling 7,724,447 shares, a drop of 9.6% from the September 15th total of 8,540,542 shares. Based on an average trading volume of 1,694,087 shares, the short-interest ratio is currently 4.6 days. Approximately 8.0% of the shares of the company are sold short.

Who are some of Transenterix's key competitors?

Who are Transenterix's key executives?

Transenterix's management team includes the folowing people:

  • Paul A. LaViolette, Independent Chairman of the Board
  • Todd M. Pope, President, Chief Executive Officer, Director
  • Joseph P. Slattery CPA, Chief Financial Officer, Executive Vice President, IR Contact Officer
  • Anthony Fernando, Chief Operating Officer
  • Andrea Biffi, Director
  • Dennis J. Dougherty, Independent Director
  • Jane H. Hsiao Ph.D., Independent Director
  • William N. Kelley M.D., Independent Director
  • Aftab R. Kherani M.D., Independent Director

How do I buy Transenterix stock?

Shares of Transenterix can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Transenterix's stock price today?

One share of Transenterix stock can currently be purchased for approximately $3.47.

MarketBeat Community Rating for Transenterix (NYSE TRXC)
Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  114 (Vote Outperform)
Underperform Votes:  99 (Vote Underperform)
Total Votes:  213
MarketBeat's community ratings are surveys of what our community members think about Transenterix and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Transenterix (NYSE:TRXC) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $2.75 (20.75% downside)
Consensus Price Target History for Transenterix (NYSE:TRXC)
Price Target History for Transenterix (NYSE:TRXC)
Analysts' Ratings History for Transenterix (NYSE:TRXC)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
3/12/2017B. RileyReiterated RatingBuy$2.75MediumView Rating Details
1/19/2017Raymond James Financial, Inc.DowngradeOutperform -> Mkt PerformN/AView Rating Details
5/16/2016Sterne Agee CRTReiterated RatingBuyN/AView Rating Details
5/11/2016Lake Street CapitalDowngradeBuy -> Hold$2.00N/AView Rating Details
4/18/2016BTIG ResearchDowngradeBuy -> Neutral$6.00N/AView Rating Details
(Data available from 10/23/2015 forward)


Earnings History for Transenterix (NYSE:TRXC)
Earnings by Quarter for Transenterix (NYSE:TRXC)
Earnings History by Quarter for Transenterix (NYSE TRXC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/6/2017Q4 2016($0.11)($0.12)ViewListenView Earnings Details
11/9/2016Q316($0.10)($0.11)$1.80 million$1.50 millionViewListenView Earnings Details
5/10/2016Q116($0.13)($0.12)ViewListenView Earnings Details
3/3/2016Q415($0.12)($0.13)ViewN/AView Earnings Details
8/6/2015Q215($0.15)($0.14)ViewN/AView Earnings Details
5/6/2015Q115($0.17)($0.16)$0.03 millionViewN/AView Earnings Details
2/24/2015Q414($0.18)($0.13)$50.00 million$0.13 millionViewN/AView Earnings Details
11/6/2014Q3($0.18)($0.18)$0.10 million$0.06 millionViewN/AView Earnings Details
5/7/2014($0.14)($0.15)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Transenterix (NYSE:TRXC)
Current Year EPS Consensus Estimate: $-0.40 EPS
Next Year EPS Consensus Estimate: $-0.37 EPS


Dividend History for Transenterix (NYSE:TRXC)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Transenterix (NYSE:TRXC)
Insider Trades by Quarter for Transenterix (NYSE:TRXC)
Institutional Ownership by Quarter for Transenterix (NYSE:TRXC)
Insider Trades by Quarter for Transenterix (NYSE:TRXC)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/4/2017S.P.A SofarMajor ShareholderBuy3,722,685$1.40$5,211,759.00View SEC Filing  
8/22/2016Andrea BiffiDirectorBuy40,000$1.40$56,000.00View SEC Filing  
6/14/2016Anthony C J FernandoCTOBuy27,000$1.46$39,420.00View SEC Filing  
5/13/2016Joseph P SlatteryCFOBuy50,000$1.92$96,000.00View SEC Filing  
11/16/2015Andrea BiffiDirectorBuy25,000$2.81$70,250.00View SEC Filing  
11/13/2015Willam N KelleyDirectorBuy20,000$2.80$56,000.00View SEC Filing  
11/12/2015Joseph P SlatteryCFOBuy15,000$2.77$41,550.00View SEC Filing  
10/2/2014Joseph P SlatteryCFOSell33,000$4.19$138,270.00View SEC Filing  
9/8/2014Richard MuellerCOOSell3,000$3.60$10,800.00View SEC Filing  
9/8/2014Todd PopeCEOSell50,000$3.70$185,000.00View SEC Filing  
4/21/2014Aisling Capital Iii LpMajor ShareholderBuy1,037,767$4.00$4,151,068.00View SEC Filing  
4/21/2014William N Starling JrDirectorBuy221,450$4.00$885,800.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Transenterix (NYSE:TRXC)
Latest Headlines for Transenterix (NYSE:TRXC)
Loading headlines, please wait.



Transenterix (TRXC) Chart for Monday, October, 23, 2017

This page was last updated on 10/23/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.